1. Home
  2. BRC vs ERAS Comparison

BRC vs ERAS Comparison

Compare BRC & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brady Corporation

BRC

Brady Corporation

HOLD

Current Price

$98.07

Market Cap

4.1B

ML Signal

HOLD

Logo Erasca Inc.

ERAS

Erasca Inc.

HOLD

Current Price

$18.08

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BRC
ERAS
Founded
1914
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.0B
IPO Year
2005
2021

Fundamental Metrics

Financial Performance
Metric
BRC
ERAS
Price
$98.07
$18.08
Analyst Decision
Hold
Strong Buy
Analyst Count
1
12
Target Price
$1.20
$14.25
AVG Volume (30 Days)
158.6K
4.9M
Earning Date
05-15-2026
05-08-2026
Dividend Yield
1.20%
N/A
EPS Growth
N/A
36.23
EPS
N/A
N/A
Revenue
$1,144,698,000.00
N/A
Revenue This Year
$7.36
N/A
Revenue Next Year
$3.57
N/A
P/E Ratio
$23.35
N/A
Revenue Growth
5.86
N/A
52 Week Low
$69.51
$1.33
52 Week High
$99.29
$24.28

Technical Indicators

Market Signals
Indicator
BRC
ERAS
Relative Strength Index (RSI) 75.53 51.57
Support Level $78.82 $17.63
Resistance Level $99.29 $18.20
Average True Range (ATR) 2.02 1.27
MACD 0.32 -0.28
Stochastic Oscillator 90.25 12.55

Price Performance

Historical Comparison
BRC
ERAS

About BRC Brady Corporation

Brady Corp provides identification solutions and workplace safety products. The company offers identification and healthcare products that are sold under the Brady brand to maintenance, repair, and operations as well as original equipment manufacturing customers. Products include safety signs and labeling systems, material identification systems, wire identification, patient identification, and people identification. Brady also provides workplace safety and compliance products such as safety and compliance signs, asset tracking labels, and first-aid products. The company is organized and managed on a geographic basis with two reportable segments: Americas & Asia which derives maximum revenue, and Europe & Australia.

About ERAS Erasca Inc.

Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.

Share on Social Networks: